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Antimicrobial susceptibility against
metronidazole and carbapenem in clinical
anaerobic isolates from Pakistan
Yusra Shafquat, Kauser Jabeen* , Joveria Farooqi, Kiran Mehmood, Seema Irfan, Rumina Hasan and Afia Zafar
Abstract
Background: Globally metronidazole and carbapenem resistance in anaerobic organisms is increasing necessitating
continuous surveillance to guide selection of empirical treatment. In this study we have determined metronidazole
resistance in anaerobes using MIC Evaluator strips (M.I.C.E strips). Carbapenem resistance was evaluated only in
metronidazole resistant isolates.
Material and methods: The study was conducted at the Aga Khan University (AKU) Hospital laboratory, Karachi,
Pakistan (2014–2017). Metronidazole and imipenem resistance was evaluated using M.I.C.E strips and minimum
inhibitory concentrations (MICs) were interpreted using Clinical Laboratory Standards Institute (CLSI) criteria. Clinical
details including demographics, prolonged hospital stay, malignancy, transplant, dialysis, diabetes, site of infection
and outcome were analyzed for association with metronidazole resistance.
Results: Of the 223 clinically significant isolates, 39 (17.5%) were metronidazole resistant (excluding the inherently
resistant organisms; for example Cutibacterium species). Imipenem resistance was determined in 29 metronidazole
resistant isolates and of these 7 (24.1%) were found to be resistant. Proportion of metronidazole resistant strains was
highest amongst Bacteroides species. A significant increase in metronidazole resistance from 12.3% in 2010–2011 to
17.5% in the current study was found. Carbapenem resistance also emerged in the period 2014–2017.
Isolates from malignancy and transplant patients showed lower odds of developing metronidazole resistance
(0.003(95% CI: 1.7–17.9)). Prolonged hospital stay was not associated with metronidazole resistance (1.1((95%
CI: 0.5–2.5)).
Conclusion: The rising trend of metronidazole resistance and emergence of carbapenem resistance in anaerobic
bacteria is alarming. Continued surveillance with strengthening of laboratory capacity regarding anaerobic susceptibility
testing is urgently needed in Pakistan.
Keywords: Anaerobic antimicrobial susceptibility, Anaerobic resistance to metronidazole, Anaerobic resistance to
carbapenem, Risk factors associated with resistance
Background
Anaerobic bacteria are known to be associated with a
number of human infections [1] including intra-
abdominal, genital tract, surgical site, brain abscesses
and skin and soft tissue infections [2]. Metronidazole is
an important first-line anti-anaerobic agent, but also
frequently used for community based infections such as
ameobiasis, giardiasis, trichomoniasis, bacterial vaginosis
and Helicobacter pylori associated gastritis and peptic
ulcer disease [3–5]. Studies show that the resistance to
metronidazole and imipenem in anaerobic organism var-
ies globally. However, emergence of strains with combined
resistance to metronidazole and carbapenem hampers
treatment and is associated with poorer outcomes [6, 7].
Guidelines therefore highlight the increasing importance
of susceptibility testing in individual settings [8, 9] .
In countries with limited laboratory capacity, isolation
and susceptibility testing of anaerobic bacteria is usually
not performed. Therefore, treatment is mostly empirical
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and if appropriate anti-anaerobic agents are not used,
treatment outcome could be affected. Hence, in such
setting there is a need for updated geographical and
clinically relevant data [10]. In addition to monitoring
trends of antimicrobial resistance, routine susceptibil-
ity testing of anaerobic organisms isolated from blood
and sterile body sites is recommended for clinical
laboratories [10, 11].
An earlier study from Pakistan conducted by same
study group during 2010–2011 had reported metronida-
zole resistance rate of 12.3% amongst anaerobic isolates
[12]. Metronidazole is one of the highly prescribed
agents in the country and as per published reports its
empirical use is 23.4% in cases of community acquired
gastroenteritis in the country to cover parasitic etiology
[5, 13]. The fact that metronidazole is easily available
“over the counter” contributes to its frequent use and
thus to the rising resistance trend [14]. Additionally, data
also shows that sales of carbapenem is highest in
Pakistan and India amongst developing countries [15].
In clinical practice, carbapenems are used as a second
line option especially in hospital settings. Although
carbapenem resistance in anaerobic organisms was not
reported from Pakistan previously, its status currently
needs evaluation especially in metronidazole resistance
strains. Therefore, in this study we aimed to determine to
metronidazole resistance in anaerobic organisms isolated
at the Aga Khan University Hospital (AKUH) Clinical
Laboratory. Additionally, carbapenem resistance was also
determined in metronidazole resistant strains. Association
between metronidazole resistance, and prolonged hospital
stay and patient outcome was also determined.
Material and methods
The cross-sectional study was conducted at the
microbiology section of the AKUH clinical laboratory
in Karachi, Pakistan. AKU hospital is a tertiary care
hospital. Clinical laboratory receives specimens from
admitted patients as well as outpatients who deposit
specimens at more than 200 collection points located
in major cities and towns of Pakistan. Consecutive
sampling technique was applied and all clinically
significant anaerobes isolated from blood, sterile body
fluids, pus, tissue and bone cultures from January
2014 to August 2017 were included. Isolates identified
as colonizers on the basis of history, source and clin-
ical data, such as localized perianal abscess, were not
included. Duplicate isolates from the same patient
isolated from more than one specimen, during the
same infectious episode or hospital admission, were
excluded (Fig. 1). The study was exempted from
ethical approval by the Institutional Ethical Review
Committee (4068-pat-ERC-16).
Clinical data
Clinical details were collected as part of laboratory
reporting protocol and included demographics, pro-
longed hospital stay, malignancy, transplant, dialysis,
Fig. 1 Flow chart showing the study design and distribution of study population on the basis of prolonged hospital stay (primary exposure)
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diabetes, site of infection and outcome, which were fur-
ther analyzed for association with metronidazole resist-
ance. Due to non-availability of data on prior antibiotic
usage, prolonged hospital stay was taken as a surrogate
for extensive antimicrobial use. We hypothesized that
the odds of metronidazole resistance will be higher in
patients with prolonged hospital stay as increased
length of hospital stay is associated with increased anti-
biotic use. Clinically significant isolates were defined as
those isolates that were isolated from either sterile sites
or non-sterile sites with symptoms and signs consistent
with anaerobic infection and require targeted therapy.
Prolonged hospital stay was defined as a hospital stay
of ≥7 days.
Isolation and identification of anaerobic bacteria
Anaerobic organisms were isolated directly from clinical
specimens as well as on subculture of the cooked meat
broth inoculated for enrichment for 24 h. The sample or
broth was inoculated on sheep blood agar with 50 μg
diagnostic metronidazole disc (Oxoid). The culture
plates were incubated in an anaerobic chamber (Concept
plus RUSKINN) for 48 h at 36 ± 1 °C. The anaerobic or-
ganisms were identified by gram stain, colony morph-
ology, aerotolerance, esculin hydrolysis in the presence
of bile, and API® 20A system (bioMerieux®, Marcy
l’Etoile, France).
Susceptibility testing
Metronidazole MIC evaluator strips (M.I.C.E), (Oxoid™,
Thermo scientific™, Basingstoke, Hants, UK) were used
to determine MICs according to the manufacturer’s
instructions. CLSI recommended Brucella agar supple-
mented with Hemin, Vitamin K1 and 5% pooled sheep
blood was used for susceptibility testing. The MICs
were read after 24 h and, in cases where it was difficult
to interpret, at 48 h. The MICs were interpreted as sen-
sitive (≤8 μg/ml) and resistant (≥16 μg/ml) using CLSI
breakpoints [16]. The MIC range, MIC50 and MIC90
were determined for metronidazole. Bacteroides fragilis
ATCC 25285 was used as control. Clinical isolates were
saved at − 80 °C in glycerol phosphate broth and metro-
nidazole resistant strains were revived to perform
imipenem susceptibilities. Due to fastidious nature of
the organisms, all the metronidazole resistant strains
could not be recovered and imipenem susceptibilities
could only be determined using M.I.C.E strips (Oxoid™,
Thermo scientific™, Basingstoke, Hants, UK) against 29
metronidazole resistant isolates.
Statistical analysis
The data obtained were entered into the statistical soft-
ware SPSS version 19.0 (SPSS, Inc., Chicago, IL). For
descriptive analysis, mean and standard deviation of
continuous variables such as age and MICs were
computed. For categorical variables, e.g. gender and anti-
biotic resistance, frequencies and percentages were
calculated. Association of risk factors with metronida-
zole resistance was determined using binomial logistic
regression to obtain odds ratios with 95% confidence
intervals (95%CI). A P-value less than 0.05 was consid-
ered significant on univariate and multivariate analysis.
Results
A total of 223 anaerobes were isolated from January
2014 to August 2017. Out of which 146 strains were
obtained from male (65.4%) and 77 from female patients
(34.5%). Isolates from patients aged < 18 year were 41/
223 (18.3%), 18–60 years were 146/223 (65.4%) and > 60
years were 36/223 (16%). Isolation of organisms varied
geographically with 78.5% (175/223) of the samples
from Sindh, 9% (20/223) from Punjab, 9% (20/223)
from Balochistan and 3.6% (8/223) from Khyber
Pakhtunkhwa. Organisms were most commonly iso-
lated from patients with intra-abdominal infections
(n = 66), bacteremia (n = 41), brain abscess (n = 12),
necrotizing fasciitis and osteomyelitis (n = 19), dia-
betic foot (n = 11), surgical site infections (n = 10),
perianal fistula and ischiorectal abscess (n = 12), ovar-
ian and uterine abscesses (n = 11), gluteal abscess
(n = 7), empyema lung (n = 6),,necrotizing otitis media
(n = 1), abscesses from other body sites and other pus
samples (n = 27). Fifty-eight percent of the isolates
were from poly-microbial infections. Clinical informa-
tion was available for 189/223 (85%) of the patients.
Of the 189 cases in which outcome could be
assessed, the case fatality rate was 5.2% (10/189).
Most commonly isolated organisms were Bacteroides
species (77%) followed by Clostridium species (18%).
Antimicrobial susceptibility data
Metronidazole resistance was detected amongst 39/223
(17.5%) isolates (Table 1). Resistance was mainly seen in
Bacteroides species (16%). MIC ranged from < 0.015
to > 256 μg/ml and MIC50 and MIC90 was 2 μg/ml
and > 256 μg/ml respectively. Seven (24.1%) of the 29
metronidazole resistant strains tested for imipenem
susceptibilities were found to be resistant. Of the 7
metronidazole sensitive strains tested for imipenem
susceptibilities, resistance was detected in only one
(14.2%). Organisms inherently resistant to metronidazole
were excluded from the comparison of metronidazole re-
sistance in both study periods. An increasing trend of re-
sistance was noted in metronidazole, as 12.4% tested
strains were metronidazole resistant in 2010–2011 [12]
compared to 17.5% in current study but the rise was found
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to be of no statistical significance (Table 1). Results were
similar when assessed individually amongst the species.
Risk factors
The frequencies of risk factors assessed during this study
are shown in Table 2; Table 3 displays the details of
regression analysis. Logistic regression was performed to
better understand which groups are at greater risk of
infections with metronidazole resistant strains, whether
acquired or inherent. The data obtained can be used to
guide physicians and surgeons about appropriate empir-
ical therapy in various infections. Amongst the anaer-
obes studied, the odds of resistance were highest in
Bacteroides species, though not statistically significant
(1.2 (95% CI: 0.5–3.0)). The chance of isolating metro-
nidazole resistant anaerobes from patients with malig-
nancy and transplant was low (5.6 (95% CI: 1.7–17.9)).
Prolonged hospital stay was not significantly associated
with metronidazole resistance (1.1 ((95% CI: 0.5–2.5)).
Discussion
A high metronidazole resistance rate (17.5%) is noted in
the current study. Emergence of carbapenem resistance
in anaerobic organisms has also been reported for the
first time in this study. Resistance was most frequently
seen in Bacteroides species which was also the most
commonly isolated organism. There is also an increasing
trend of metronidazole resistance (12.4% in 2010–2011
to 17.5% in 2014–2017) [12]. Previous study conducted
by the same group assessing resistance in clinical anaer-
obic isolates collected from AKUH laboratory using
similar sampling strategy had reported 12.4% metronida-
zole resistance. The susceptibility method used in the
previous study was CLSI recommended agar dilution,
while this study has been conducted using comparable
Table 1 Trends in antimicrobial resistance of anaerobes in Pakistan from 2014 to 2017 compared with 2010–2011 [12]
Organisms n = 223 Metronidazole
resistance
(2014–2017)
n (%)
Metronidazole
resistance
(2010–2011)
n (%)
P value
(Pearson chi square)
Frequency of isolates
tested for imipenem
(n = 29)
n (%)
Imipenem
resistance
(n = 7)
n (%)
Imipenem
resistance
(2010–2011)
N = 0/106
Overall resistance (excluding
inherent resistance)
39/223 (17.4)) 13/106 (12.3) 0.184 – 7/29
(24.1)
0/106
Bacteroides fragilis 97 20 (20.6) 6/39 (15.3) 0.483 21 6 0
Bacteroides species 74 16 (21.6) 06/28(18) 0.983 5 1(27) 0
Clostridium species 39 2 (5) 1/32 (3) 0.676 3 0 0
Fusobacterium speciesa 3 0 0/1 (0) – – – –
Prevotella speciesa 3 1 (33) 0/6 (0) – – – 0
Cutibacterium species 5 5b – – – – –
Bifidobacterium speciesa 1 1b – – – –
Eggerthella lentaa 1 1b – – – –
Species marked (a) were included in “Other” category in regression analysis for association with drug resistance
b Species inherently resistant to metronidazole - Organisms inherently resistant to metronidazole were not included in the comparison of metronidazole resistance between
the two study periods
Table 2 Overall frequency of risk factors and amongst
metronidazole and imipenem resistant strains
Risk factors Total (189) Metronidazole
resistance
(total = 33)
Imipenem
resistance
(total = 26
metronidazole
resistant strains)
N (%) N (%) N (%)
Age
< 18 years 31 (16.4) 3 (9.09) 1 (3.8)
18–60 years 126 (66.7) 24 (72.7) 3 (11.5)
> 60 years 32 (16.9) 6 (18.2) 3 (11.5)
Gender
Male 129 (68.2) 26 (78.8) 7 (26.9)
Female 60 (31.7) 7 (21.2) 0
Prolonged hospital staya 43 (22.7) 9 (27.3) 3 (11.5)
Diabetes Mellitus 26 (13.7) 2 (6.06) 0
Malignancy/Transplant 11 (5.82) 5 (15.1) 1 (3.8)
Dialysis 2 (1.06) 1 (3.03) 0
Bacteremia 35 (18.5) 9 (27.3) 3 (11.5)
Skin and soft tissue
infections
49 (25.9) 6 (18.2) 1 (3.8)
Head and neck infections 18 (9.52) 1 (3.03) 0
Intra-abdominal infections 66 (34.9) 13 (39.4) 2 (7.7)
Empyema lung 6 (3.17) 2 (6.06) 1 (3.8)
Genitourinary tract
infections
17 (8.99) 2 (6.06) 0
Expired 10 (5.29) 3 (9.09) 3 (11.5)
aPrimary exposure
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methodology i.e. exponential gradient method. The find-
ings of both studies reflect the rising trend of antimicro-
bial resistance in anaerobes in Pakistan and necessitate
the need of routine susceptibility testing across labora-
tories in Pakistan. However, there are several limitations
in establishing anaerobic susceptibility testing in the
country. Firstly, isolation of anaerobes requires special
environment and media, which is not available in many
diagnostic laboratories. In addition, disc diffusion due to
its ease and low cost is the most commonly used
method of susceptibility testing. Disc diffusion tech-
nique for the susceptibility testing of anaerobes has
not been recommended by both CLSI and EUCAST,
although a study has shown good agreement between
disk diffusion and agar dilution method in Bacteroides
species for metronidazole and imipenem [17]. Agar
dilution for anaerobe susceptibility requires expertise
and is not feasible for most local laboratories. Use of
M.I.C.E strips and E-test have good correlation with
agar dilution and are reliable, but are expensive for
laboratories with limited resources [18, 19]. Hence we
suggest investment in financial terms and capacity
building of staff in both public and private sector
laboratories across Pakistan to promote accurate
reporting of susceptibility testing.
Multiple centers worldwide have reported increasing
metronidazole resistance in anaerobes, mainly in
Bacteroides species. In a meta-analysis conducted in
France over an interval of 11 years, a 2.8 fold rise in
metronidazole resistance was observed in Bacteroides
and Parabacteroides species [10]. Similarly in other
studies conducted in Ontario, Canada, South Africa and
Croatia, India, 1.2, 8, 2.9 and 24.5% of the Bacteroides
species were found to be resistant to metronidazole re-
spectively [1, 20–22]. In another study from Netherlands,
4% of the Prevotella species were found resistant to
metronidazole [11]. A comparative analysis of 11 year data
of anaerobe antimicrobial susceptibility conducted in
Kuwait demonstrated metronidazole resistance rate to be
as high as 2.7% in Bacteroides fragilis and 5.6% in
Bacteroides ovatus respectively [2]. Global emergence of
metronidazole resistance has led to use of carbapenem for
the treatment of complicated intra-abdominal infections.
A study conducted in Taiwan, over a period of 16 years,
reported imipenem and meropenem resistance in 7 and
12% of B. fragilis isolates, 4 and 8% of Fusobacterium
Table 3 Univariate and multivariate analysis of the risk factors identified. All those with statistically significant Odds Ratios, at 95%
confidence, are in bold
Metronidazole resistance as outcome (n = 189)
Univariate analysis Multivariate analysis
Clinical characteristics OR (95% CI) P Value OR(95% CI) P Value
Prolonged hospital stayb (≥ 7 days of hospital admission) 1.1 (0.5–2.5) 0.869 0.6 (0.2–1.7) 0.381
Age group (< 18 years as reference) 0.338
18–60 years 2.6 (0.7–9.0) 0.144
> 60 years 2.5 (0.6–10.7) 0.214
Female (Male as reference) 0.5 (0.2–1.2) 0.128
Organisms (Clostridium species as reference) 0.876
Bacteroides fragilis 0.6 (0.06–5.1) 0.611
Bacteroides other than fragilis 1.2 (0.5–3.0) 0.662
Othersa 1.016 (0.3–3.1) 0.978
Diabetes Mellitus 0.3 (0.06–1.3) 0.119
Malignancy/transplant 5.6 (1.7–17.9) 0.003 6.3(1.7–23.3) 0.005
Dialysis 4.2(0.2–68.5) 0.315
Bacteremia 2.3 (1.0–5.1) 0.041 2.1 (0.9–4.7) 0.089
Skin and soft tissue infection 0.6 (0.2–1.3) 0.181
Head and neck infections 0.4 (0.09–2.0) 0.302
Intraabdominal infections 1.1 (0.5–2.4) 0.739
Respiratory tract infections 2.1 (0.4–11.9) 0.399
Genitourinary infections 0.5 (0.1–2.4) 0.402
Expired 2.5 (0.7–9.0) 0.161
a “Other” category includes Fusobacterium species, Cutibacterium species, Prevotella, Bifidobacterium, Eggerthella lenta
bprimary exposure
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species and 15 and 0% of Clostridium respectively [23]. In
a European antibiotic susceptibility survey, conducted in
2000, 25/1284 Bacteroides strains were positive for cfiA
carbapenem resistance gene and their study data exhibits
a resistance rate of 0.8 and 1.3% for imipenem and mero-
penem respectively [9]. In a national survey conducted in
Denmark, 3.9% of the Bacteroides fragilis isolates were
resistant to meropenem whereas none of the isolates were
resistant to metronidazole [24].
Metronidazole is one of the most commonly used
antibiotic for the management of anaerobic infections
especially Bacteroides fragilis infections. It is also being
prescribed for prophylaxis, empirical and targeted therapy
for many other infections in Pakistan. Although prior or
prolonged metronidazole usage and development of resist-
ance has been well reported for Helicobacter associated
gastritis, studies reporting association of metronidazole
overuse and emergence of resistance in anaerobic organ-
isms are not available [25]. In vitro studies suggest that
prolonged exposure of metronidazole to nim gene carry-
ing anaerobes could lead to resistance [26]. A case control
study evaluating risk factors for development of resistance
against beta-lactam/beta-lactamase inhibitors in patients
with Bacteroides bacteremia have identified duration of
exposure as an independent risk factor of resistance [27].
Another study evaluating antibiotic exposure in past
2 years and isolation of resistant anaerobes from stool
samples had shown an association with meropenem
exposure and reduced susceptibility to meropenem. No
association was found for metronidazole, clindamycin or
piperacillin-tazobactam resistance [28]. In our study due
to lack of reliable antibiotic usage data, we could not
assess prior or prolonged use of metronidazole as a driver
for resistance. Prolonged hospital stay was used as a surro-
gate for prolonged usage of metronidazole. Our findings
suggest that prolonged hospital stay was not signifi-
cantly associated with metronidazole resistance and
probably not a good surrogate for prolonged anti-
biotic use. Further studies are required for assessment
of relation of prolonged hospital stay and antibiotic
usage to acquired resistance.
Imipenem is now widely used in hospital settings in
case of complicated intra-abdominal infections. The
previous data from Pakistan showed no resistance to
carbapenems whereas our study shows 24.1% of imipe-
nem resistance in metronidazole resistant strains,
reflecting emerging resistance to carbapenems [12].
Imipenem resistance was also seen in at least one of the
metronidazole susceptible isolates tested.
Our analysis showed that patients with malignancy or
history of transplant had lesser chances of developing
metronidazole resistance. Our study however lacked
details on severity of disease, data of patient assessment
using critical care scoring systems (APACHE II and
SOFA scores) and antimicrobial therapy (single drug or
combined regimen). A previous study conducted in our
setup showed higher proportion of metronidazole resist-
ance in patients with bacteremia [12]. However, this ana-
lysis showed that anaerobic strains isolated from cases of
bacteremia had lower odds of metronidazole resistance.
The strength of this study is that this could be used as
a baseline to guide future initiatives in implementing
anaerobic susceptibility and subsequent generation of
data of trends of antimicrobial resistance. There were
however some major limitations of this study. This study
was laboratory based study conducted in Southern
Pakistan; hence an uneven distribution of isolates from
other parts of the country was seen. The results there-
fore may not be generalizable to the whole country.
Similarly, due to limited access to clinical data, associ-
ation of other risk factors including prolonged antibiotic
usage and detailed clinical status of cases could not be
assessed. Finally, sample size for imipenem resistance;
determined primarily in metronidazole resistant strains,
was limited.
Conclusion
In summary, an alarming 17.5% resistance amongst
anaerobes against metronidazole is observed in this
study. This resistance does not seem to be associated
with bacteremia or mortality. However other risk factors
like prior use of anti-anaerobic agents were not explored
and may be important to evaluate in future. We also
need to study the outcomes of antimicrobial resistance
in anaerobes to understand its impact on individual
patients and on public health. Due to emerging drug
resistance in anaerobes, newer and alternative options
for management also need to be explored. It is time that
susceptibility testing of anaerobes should be a routine
service, to guide physicians for proper management.
This data may help in surveillance of resistance and in
generating local antibiogram and can be used for peri-
odic surveillance of resistance trend.
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